NL-OMON42832已完成不适用
ImmunoModulation by the Combination of Ipilimumab and nivolumab neoadjuvant to Surgery In advanced Or recurrent Head and Neck Carcinoma, (IMCISION), a phase-Ib/II trial. Subtitle: Hypoxia as a determinant for the effect of nivolumab with or without ipilimumab on intra-tumoral T cell capacity - Immunotherapy neoadjuvant to surgery in head and neck carcinoma (IMCISION)
Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 32 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. No immunosuppressive medications prior study inclusion, adults age > 18 years, and
- •2. Histologically confirmed T3-4N0-3M0 HNSCC (with soft tissue infiltration depth of * 1 cm) of the oral cavity, oropharynx, hypopharynx or supraglottic larynx, eligible for curative surgery as primary treatment or salvage surgery after failed (chemo)radiation.
- •3. WHO 0-1
排除标准
- •- Distant metastasis
- •- Autoimmune disease
- •- A condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of study drug administration.
- •- Prior systemic treatment with immunotherapy targeting T-cell costimulation or immune checkpoint pathways;
- •- Hepatitis B / C, HIV or (AIDS);
- •- Pregnant or nursing.
研究者
相似试验
进行中（未招募）
1 期
Ipilimumab in combination with Nivolumab followed by Nivolumab monotherapy in patients with unresectable or oligometastatic melanoma.Patients with histologically or cytologically confirmed AJCC (8th ed.) Stage IIIB -IV resectable melanoma.MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2018-002172-40-ITISTITUTO EUROPEO DI ONCOLOGIA35
进行中（未招募）
不适用
A Phase II Study of the Combination of Ipilimumab and Fotemustine in Patients with Unresectable Locally Advanced or Metastatic Malignant Melanoma - NIBIT-M1EUCTR2010-019356-50-ITIBIT (NETWORK ITALIANO PER LA BIO-IMMUNOTERAPIA DEI TUMORI)
已完成
不适用
ivolumab plus Ipilimumab versus existing immunotherapies in patients with PD-L1-positive advanced non-small cell lung cancer: a systematic review and network meta-analysis.PD-L1-positive previously untreated advanced non-small cell lung cancerJPRN-UMIN000039784Showa University School of Medicine4,011
进行中（未招募）
1 期
A Study of Nivolumab and Ipilimumab Combined with Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA)Stage IV Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 20.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001195-35-ESBristol-Myers Squibb International Corporation504
进行中（未招募）
1 期
A Study of Nivolumab and Ipilimumab Combined with Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA)Stage IV Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 20.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001195-35-FRBristol-Myers Squibb International Corporation504